Blink Health, an app that helps people save money on prescription medications, raises $90M Series B led by 8VC, briging total raised to $165M
Blink Health, a company that provides discounts to prescription drugs, just raised another $90 million. — The New York-based digital health startup …
Context & Ripple Effects
Blink Health's $90M Series B, led by 8VC and lifting total funding to $165M, lands inside a broader run of venture money into software layered over the drug value chain: BrightInsight later raised a $101M Series C at a reported $750M valuation for apps connecting drug and device makers to patients, while Xealth built a platform for providers to manage non-drug prescriptions like health apps and insulin monitors.
One housekeeping note for readers tracking this company: the corpus also contains a completely separate startup named Blink — a London-born frontline-worker messaging app that raised its own $20M Series A at a $100M valuation before relocating to New York — so the two Blinks' funding histories should not be conflated.
First-order effects
- The round gives New York-based Blink Health $165M in cumulative backing to scale its prescription-discount app, with 8VC now anchoring the cap table as lead investor.
- Blink Health enters the same nine-figure funding tier as BrightInsight, confirming investors will back both patient-side discount plays and maker-side app infrastructure in parallel.
Second-order effects
- Capital piling into both ends of the medication journey — Blink Health negotiating prices down for consumers, BrightInsight building compliance-grade apps for manufacturers — pushes competition toward whoever controls the digital touchpoint closest to the patient.
- Xealth's expansion of 'prescription' to cover apps and devices signals that pharmacy channels may soon distribute software alongside pills, widening the market Blink Health's discount model operates in.
Third-order effects
- If the funding pattern holds, drug pricing becomes an intermediated software market: venture-backed platforms sit between patients, prescribers, and manufacturers, capturing margin from the traditional pharmacy-benefit stack without owning any physical supply.
- Brand collision is a structural side effect of crowded digital health — two unrelated companies named Blink raising institutional rounds shows how quickly category naming conventions saturate as capital floods in.
The trend: Venture capital is systematically funding software intermediaries across the prescription drug economy, from consumer discounts to manufacturer-built patient apps.